Serina Therapeutics, Inc. (SER) stock
SERNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.41−0.09 (-6.00%)
Close on Nov 12, 2026Market cap $35.81MP/E –Yield –
Serina Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Serina Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $15.04M, up 24.1% year over year. For fiscal 2025 it was $13.16M, up 75.9% from the year before. The highest annual figure on record is $13.16M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.16M | +75.9% |
| FY2024 | Dec 31, 2024 | $7.48M | +213.2% |
| FY2023 | Dec 31, 2023 | $2.39M | +133.0% |
| FY2022 | Dec 31, 2022 | $1.03M | -29.6% |
| FY2021 | Dec 31, 2021 | $1.46M | -60.8% |
| FY2020 | Dec 31, 2020 | $3.71M | -37.1% |
| FY2019 | Dec 31, 2019 | $5.90M | +1.3% |
| FY2018 | Dec 31, 2018 | $5.83M | +0.8% |
| FY2017 | Dec 31, 2017 | $5.78M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.63M | +26.7% |
| Q2 FY2026 | Jun 30, 2026 | $3.82M | +21.1% |
| Q1 FY2026 | Mar 31, 2026 | $3.20M | +8.4% |
| Q4 FY2025 | Dec 31, 2025 | $3.40M | +43.8% |
| Q3 FY2025 | Sep 30, 2025 | $3.65M | +51.2% |
| Q2 FY2025 | Jun 30, 2025 | $3.15M | +97.7% |
| Q1 FY2025 | Mar 31, 2025 | $2.95M | +166.8% |
| Q4 FY2024 | Dec 31, 2024 | $2.37M | +160.7% |
| Q3 FY2024 | Sep 30, 2024 | $2.42M | +300.5% |
| Q2 FY2024 | Jun 30, 2024 | $1.59M | +232.8% |
| Q1 FY2024 | Mar 31, 2024 | $1.11M | +177.2% |
| Q4 FY2023 | Dec 31, 2023 | $907.00K | +336.1% |
| Q3 FY2023 | Sep 30, 2023 | $603.00K | +272.2% |
| Q2 FY2023 | Jun 30, 2023 | $479.00K | +84.9% |
| Q1 FY2023 | Mar 31, 2023 | $399.00K | +0.8% |
| Q4 FY2022 | Dec 31, 2022 | $208.00K | -44.7% |
| Q3 FY2022 | Sep 30, 2022 | $162.00K | -41.1% |
| Q2 FY2022 | Jun 30, 2022 | $259.00K | -46.2% |
| Q1 FY2022 | Mar 31, 2022 | $396.00K | +22.2% |
| Q4 FY2021 | Dec 31, 2021 | $376.00K | -58.5% |
| Q3 FY2021 | Sep 30, 2021 | $275.00K | -57.9% |
| Q2 FY2021 | Jun 30, 2021 | $481.00K | -48.6% |
| Q1 FY2021 | Mar 31, 2021 | $324.00K | -73.5% |
| Q4 FY2020 | Dec 31, 2020 | $905.00K | -38.4% |
| Q3 FY2020 | Sep 30, 2020 | $653.00K | -54.9% |
| Q2 FY2020 | Jun 30, 2020 | $935.00K | -43.3% |
| Q1 FY2020 | Mar 31, 2020 | $1.22M | -8.7% |
| Q4 FY2019 | Dec 31, 2019 | $1.47M | -3.5% |
| Q3 FY2019 | Sep 30, 2019 | $1.45M | +8.6% |
| Q2 FY2019 | Jun 30, 2019 | $1.65M | +19.2% |
| Q1 FY2019 | Mar 31, 2019 | $1.34M | -15.9% |
| Q4 FY2018 | Dec 31, 2018 | $1.52M | – |
| Q3 FY2018 | Sep 30, 2018 | $1.33M | – |
| Q2 FY2018 | Jun 30, 2018 | $1.38M | – |
| Q1 FY2018 | Mar 31, 2018 | $1.59M | – |
See a number that looks wrong?